Search results
Results from the WOW.Com Content Network
Number of employees. 407 (2023) ... Massachusetts, San Francisco, California and London, United Kingdom. ... CRISPR Therapeutics was founded in 2013 by Emmanuelle ...
The next two years may be a bit financially tight for CRISPR Therapeutics, which represents a risk for those who buy the stock now. As of the second quarter, it has about $484 million in cash ...
CRISPR Therapeutics has two next generation approaches with the potential to significantly expand the addressable population with SCD and TDT. The Company continues to advance its internally developed targeted conditioning program, an anti-CD117 (c-Kit) antibody-drug conjugate (ADC), through preclinical studies.
ZUG, Switzerland and BOSTON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today presented data from the Company’s ongoing Phase 1/2 dose escalation clinical trial evaluating the safety and efficacy of CTX112™, a ...
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CRISPR Therapeutics wasn’t one of them. The 10 stocks that ...
For premium support please call: 800-290-4726 more ways to reach us
CasPEDIA — a wiki-style database of the known CRISPR-associated (Cas) proteins, their activity and use cases, launched in 2023 by a group of researchers at the IGI. [71] CRISPR Clinical Trials — an annual summary of CRISPR-based therapies currently in clinical trials, broken down by disease area. [72]
For premium support please call: 800-290-4726 more ways to reach us